Christian U. Blank
克里斯蒂安·布兰克
MD, PhD
Professor of Translational Immuno-Oncology; Senior Oncologist, Melanoma Unit转化免疫肿瘤学教授；黑色素瘤部门高级肿瘤学家
👥Biography 个人简介
Professor Blank pioneered neoadjuvant immunotherapy for resectable melanoma with the OpACIN and OpACIN-neo trials, and served as a principal investigator on the RELATIVITY-047 trial of nivolumab plus relatlimab (LAG-3 blockade). He is a leading voice on the tumor microenvironment and immune evasion.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Neoadjuvant IO (OpACIN / OpACIN-neo)
Designed and led the OpACIN series, establishing that neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and may replace adjuvant therapy in resectable stage III melanoma.
LAG-3 Biology and RELATIVITY-047
Contributed to translational science underpinning nivolumab plus relatlimab, elucidating LAG-3 as a non-redundant checkpoint improving PFS in frontline advanced melanoma.
Representative Works 代表性著作
Neoadjuvant ipilimumab plus nivolumab in resectable stage III melanoma (OpACIN-neo): a multicenter, phase 2 trial
Nature Medicine (2019)
Defined optimal dose/schedule of neoadjuvant dual IO yielding 57% pCR with manageable toxicity.
Nivolumab plus relatlimab as first-line treatment for advanced melanoma (RELATIVITY-047): extended follow-up
Journal of Clinical Oncology (2023)
Updated survival data confirming PFS benefit of LAG-3 plus PD-1 dual blockade as new frontline standard.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 克里斯蒂安·布兰克 的研究动态
Follow Christian U. Blank's research updates
留下邮箱，当我们发布与 Christian U. Blank（Netherlands Cancer Institute – Antoni van Leeuwenhoek (NKI-AVL)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment